Ricardo Sepulveda, MD
Ophthalmology · San Antonio, TXNPI 1013177799
Payments from drug & device makers
Across 171 payments — averaging $38.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$1K
- Alcon$831
- AbbVie$743
- Bausch & Lomb, A Division Of Bausch Health US, LLC$490
- Biotissue Holdings Inc.$461
- Rxsight Inc$454
- plus $2K from 21 others
What the payments were for
- Food & beverage$6,46498%
- Other$1402%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 28 | $1,246 |
| Alcon | 35 | $831 |
| AbbVie(2 entities) | 24 | $743 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $490 |
| Biotissue Holdings Inc. | 6 | $461 |
| Rxsight Inc | 8 | $454 |
| Bausch & Lomb Americas Inc. | 5 | $341 |
| Ocular Therapeutix, Inc. | 4 | $277 |
| Johnson & Johnson Surgical Vision, Inc. | 10 | $266 |
| Ivantis, Inc | 4 | $247 |
| Novartis | 7 | $212 |
| Regeneron | 1 | $150 |
| Rayner Intraocular Lenses Limited | 2 | $144 |
| Mallinckrodt Hospital Products Inc. | 2 | $143 |
| Kala Pharmaceuticals, Inc. | 4 | $141 |
| Tarsus Pharmaceuticals, Inc. | 4 | $102 |
| Optovue, Inc. | 1 | $66 |
| Oyster Point Pharma, Inc. | 2 | $47 |
| Akorn Operating Company LLC | 2 | $38 |
| Sight Sciences, Inc. | 2 | $37 |
| Shire North American Group Inc | 2 | $32 |
| Tearlab Corp | 2 | $29 |
| Genentech USA, Inc. | 1 | $25 |
| Amgen | 1 | $25 |
| Akorn, Inc. | 1 | $21 |
| Lensar, Inc. | 2 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$345
- RXSIGHT CONTACT LENS$330
- RXSIGHT INJECTOR CARTRIDGE$330
- RXSIGHT INJECTOR HANDPIECE$330
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$330
- KXL System$288
- STELLARIS$248
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$229
- Hydrus Microstent$164
- EYLEA HD$150
- iStent infinite Trabecular Micro-Bypass System Model iS3$145
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$145
- Photrexa$143
- RayOne EMV$125
- RayOne Spheric$125
- RayOne Aspheric$125
- enVista MX60 IOL$125
- ACTHAR$122
- AcrySof IQ PanOptix$117
- Tecnis IOL$117
How this compares
$6,604 in reported general payments places this provider in the 75th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 413 | $16,018 |
| RestasisCyclosporine | 20 | $15,270 |
| MoxifloxacinMoxifloxacin Hcl | 370 | $15,195 |
| Ketorolac Tromethamine | 402 | $12,217 |
| CombiganBrimonidine Tartrate/Timolol | 23 | $8,721 |
| LumiganBimatoprost | 14 | $7,585 |
| VyzultaLatanoprostene Bunod | 19 | $7,301 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 52 | $5,945 |
| Cyclosporine | 13 | $3,776 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 15 | $3,133 |
| Latanoprost | 325 | $2,340 |
| Brimonidine Tartrate | 41 | $1,609 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 102 | $1,275 |
| Acetazolamide | 22 | $773 |
| Dorzolamide Hcl | 25 | $432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan | $743 | $31,57657 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $341 | $7,30119 claims |
| AlconSimbrinza | $831 | $3,13315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in San Antonio
- Michael SingerSan Antonio$4.2M
- Gregory ParkhurstSan Antonio$4.1M
- Calvin MeinSan Antonio$1.3M
- James LehmannSan Antonio$1.1M
- Darren BellSan Antonio$906K
- Gregory BruninSan Antonio$709K
- Richard EvansSan Antonio$656K
- Edward RashidSan Antonio$523K
- Kenneth MaverickSan Antonio$485K
- Kundandeep NagiSan Antonio$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.